The Effect of Short-Term Treatment with Equine Serum Versus Conditioned Equine
or Canine Serum in Three Research Dogs with Spontaneous Keratoconjunctivitis Sicca:
A Case Series Pilot Study
Jacqueline Peraza1, Katrina Jones1, Kathryn Wotman1, David D Frisbie1,2
and Michala de Linde Henriksen1*
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical
Sciences, Colorado State University, Fort Collins, Colorado
Wayne McIlwraith Translational Medicine Institute, College of Veterinary Medicine
and Biomedical Sciences, Colorado State University, Fort Collin, Colorado
*Corresponding Author: Michala de Linde Henriksen, Department of Clinical
Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State
University, Fort Collins, Colorado.
March 20, 2023; Published: April 03, 2023
Objective: To compare the safety and short-term clinical effect of three serum types [equine serum (ES), ‘equine interleukin-1 receptor antagonist protein’ serum (eq-IRAP), and canine IRAP serum (ca-IRAP)] on keratoconjunctivitis sicca (KCS) in dogs.
Animals Studied: Three research dogs diagnosed with spontaneous KCS.
Procedures: Each dog was treated for three days, three times a day (TID) in both eyes (OU) with ES, followed by three days of treatment with eq-IRAP TID OU, followed by three days treatment with ca-IRAP TID OU. Clinical parameters (discharge, conjunctival
hyperemia, chemosis) were scored on the last treatment day for each serum type. Schirmer tear test (STT) was measured throughout the study. The three different serum types were analyzed with ELISA kits for the concentration of equine interleukin-1 receptor
antagonist (eq-IL-1Ra), and ca-IL-1Ra.
Results: All three serum types were well tolerated in the three dogs. Subjectively, dogs treated with ca-IRAP showed improved
clinical parameters such as decreased conjunctival hyperemia. Objectively, no differences in STT were seen between the groups (P >
0.05). The highest concentration of IRAP was found in ca-IRAP analyzed for ca-IL-1Ra (299.7 pg/mL).
Conclusion: Topical ca-IRAP was noted to have the most significant clinical effect on evaluated parameters. Future long-term studies
are needed to confirm the potential anti-inflammatory effect of topical ca-IRAP
Keywords: Conjunctivitis, Cytokines, Interleukin-1 receptor antagonist protein, Interleukin-1 receptor antagonist, IRAP, KCS.
- Berdoulay A., et al. “Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca”. Veterinary Ophthalmology 4 (2005): 225-232.
- Williams DL. “Immunopathogenesis of keratoconjunctivitis sicca in the dog”. Veterinary Clinics of North America: Small Animal Practice 2 (2008): 251-268.
- Giuliano EA. “Chapter 17: Diseases and surgery of the canine lacrimal secretory system. In: Gelatt KN, ed”. Veterinary Ophthalmology. 6th Wiley Blackwell (2021): 1008-1044.
- Moore CP. “Qualitative tear film disease”. Veterinary Clinics of North America: Small Animal Practice 3 (1990): 565-581.
- Larsen K., et al. “Sjogren’s syndrome treated with bromhexine: A randomized clinical study”. British Medical Journal 1 (1978): 1579-1581.
- Patel R and Shahane A. “The epidemiology of Sjogren’s syndrome”. Dove Press 6 (2014): 247-255.
- Cohen SB., et al. “A multicentre, double blind, randomized, placebo controlled trial of Anakinta (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate”. Annals of Rheumatic Diseases 63 (2004): 1062-1068.
- Amparo F., et al. “Topical interleukin 1 receptor antagonist for treatment of dry eye disease”. JAMA Ophthalmology 6 (2013): 715-723.
- Frisbie DD., et al. “Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene”. Gene Therapy 1 (2003): 12-20.
- Bogers SH. “Cell-based therapies for joint disease in veterinary medicine: What we have learned and what we need to know”. Frontiers in Veterinary Science 7 (2018): 1-17.
- Lourenco-Martins AM., et al. “Allergic conjunctivitis and conjunctival provocation tests in atopic dogs”. Veterinary Ophthalmology4 (2011): 248-256.
- Featherstone HJ and Heinrich CL. “Chapter 10: Ophthalmic examination and diagnostics, Part 1. In: Gelatt KN, ed. Veterinary Ophthalmology. 6th Wiley Blackwell (2021): 564-661.
- Dodi PL. “Immune-mediated keratoconjunctivitis sicca in dogs: Current perspectives on management”. Veterinary Medicine (Auckland, N.Z.)6 (2015): 341-347.
- Sawyere DM., et al. “Cytokine and growth factor concentrations in canine autologous conditioned serum”. Veterinary Surgery 5 (2016): 582-586.
- Koussounadis AI., et al. “Analysis of fish IL-1β and derived peptide sequences indicates conserved structures with species-specific IL-1 receptor binding: Implications for pharmacological Design”. Current Pharmaceutical Design 31 (2004): 3857-3871.
- Hraha TH., et al. “Autologous conditioned serum: The comparative cytokine profiles of two commercial methods (IRAP and IRAP II) using Equine blood”. Equine Veterinary Journal 5 (2011): 516-521.
- Hohenhaus AE. “Blood transfusion and blood substitutes”. Fluid, Electrolyte, and acid-base Disorders in Small Animal Practice (2006): 567-583.
- Diehl KH., et al. “A good practice guide to the administration of substances and removal of blood, including routes and volumes”. Journal of Applied Toxicology 1 (2001): 15-23.
- Huggins SS., et al. “Serum concentrations of canine interleukin-1 receptor antagonist protein in healthy dogs after incubation using an autologous serum processing system”. Research in Veterinary Science 101 (2015): 28-33.
- Strauss RA., et al. “Evaluation of microbial contamination of canine plasma eyedropper bottles following clinical use in canine patients”. Veterinary Ophthalmology3 (2019): 222-228.